A retrospective analysis of 551 lung cancer patients from 24 centers in 10 countries revealed that in the 16 patients with RET fusion-positive NSCLC, ICI monotherapy achieved an ORR of only 6% and a median PFS of 2.1 months, which were overall lower compared to the responses of patients with other driver mutations such as EGFR, KRAS, and BRAF (22). The gene discussed is BRAF; the disease is lung cancer.